Marco Capezzone

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1736688/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Disappearance of Humoral Thyroid Autoimmunity after Complete Removal of Thyroid Antigens. Annals of Internal Medicine, 2003, 139, 346.	2.0	307
2	Impact of Proto-Oncogene Mutation Detection in Cytological Specimens from Thyroid Nodules Improves the Diagnostic Accuracy of Cytology. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1365-1369.	1.8	295
3	Diagnostic 131-lodine Whole-Body Scan May Be Avoided in Thyroid Cancer Patients Who Have Undetectable Stimulated Serum Tg Levels After Initial Treatment. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1499-1501.	1.8	260
4	Minimally invasive video-assisted thyroidectomy for papillary carcinoma: A prospective study of its completeness. Surgery, 2002, 132, 1070-1074.	1.0	199
5	Prediction of Disease Status by Recombinant Human TSH-Stimulated Serum Tg in the Postsurgical Follow-Up of Differentiated Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5686-5690.	1.8	167
6	Contralateral Papillary Thyroid Cancer is Frequent at Completion Thyroidectomy with No Difference in Low- and High-Risk Patients. Thyroid, 2001, 11, 877-881.	2.4	140
7	Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity. Endocrine-Related Cancer, 2008, 15, 1075-1081.	1.6	119
8	Limited Value of Repeat Recombinant Human Thyrotropin (rhTSH)-Stimulated Thyroglobulin Testing in Differentiated Thyroid Carcinoma Patients with Previous Negative rhTSH-Stimulated Thyroglobulin and Undetectable Basal Serum Thyroglobulin Levels. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 76-81.	1.8	112
9	Clinical Features and Therapeutic Implication of Papillary Thyroid Microcarcinoma. Thyroid, 2007, 17, 1085-1092.	2.4	98
10	Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. European Journal of Endocrinology, 2001, 144, 5-11.	1.9	92
11	Short Telomeres, Telomerase Reverse Transcriptase Gene Amplification, and Increased Telomerase Activity in the Blood of Familial Papillary Thyroid Cancer Patients. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3950-3957.	1.8	80
12	Activation of Nicotinamide N-Methyltransferase Gene Promoter by Hepatocyte Nuclear Factor-1β in Human Papillary Thyroid Cancer Cells. Molecular Endocrinology, 2005, 19, 527-539.	3.7	58
13	RET protein expression has no prognostic impact on the long-term outcome of papillary thyroid carcinoma. European Journal of Endocrinology, 2001, 145, 599-604.	1.9	50
14	Telomere Abnormalities and Chromosome Fragility in Patients Affected by Familial Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1327-E1331.	1.8	31
15	Familial non-medullary thyroid cancer: a critical review. Journal of Endocrinological Investigation, 2021, 44, 943-950.	1.8	31
16	Telomere Length in Neoplastic and Nonneoplastic Tissues of Patients with Familial and Sporadic Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1852-E1856.	1.8	28
17	Lack of germline A339V mutation in thyroid transcription factor-1 (TITF-1/NKX2.1) gene in familial papillary thyroid cancer. Thyroid Research, 2010, 3, 4.	0.7	25
18	Small papillary thyroid carcinoma with minimal extrathyroidal extension should be managed as ATA low-risk tumor. Journal of Endocrinological Investigation, 2018, 41, 1029-1035.	1.8	24

MARCO CAPEZZONE

#	Article	IF	CITATIONS
19	Prospective Validation of ATA and ETA Sonographic Pattern Risk of Thyroid Nodules Selected for FNAC. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2362-2368.	1.8	19
20	Telomeres and Thyroid Cancer. Current Genomics, 2009, 10, 526-533.	0.7	16
21	Lack of Mutations of the Telomerase RNA Component in Familial Papillary Thyroid Cancer with Short Telomeres. Thyroid, 2012, 22, 363-368.	2.4	15
22	Use of Surgical Gamma Probe for the Detection of Lymph Node Metastases in Differentiated Thyroid Cancer. Tumori, 2000, 86, 367-369.	0.6	12
23	Telomerase and the endocrine system. Nature Reviews Endocrinology, 2011, 7, 420-430.	4.3	12
24	Should familial disease be considered as a negative prognostic factor in micropapillary thyroid carcinoma?. Journal of Endocrinological Investigation, 2019, 42, 1205-1213.	1.8	12
25	Rare diseases in clinical endocrinology: a taxonomic classification system. Journal of Endocrinological Investigation, 2015, 38, 193-259.	1.8	11
26	Validation of American Thyroid Association Ultrasound Risk-Adapted Approach for Repeating Cytology in Benign Thyroid Nodules. Thyroid, 2021, 31, 446-451.	2.4	11
27	Silent thyroiditis following vaccination against COVID-19: report of two cases. Journal of Endocrinological Investigation, 2022, 45, 1079.	1.8	11
28	Increasing incidence of thyroid cancer in Basilicata: An Italian study. Journal of Endocrinological Investigation, 2007, 30, 507-512.	1.8	9
29	Long-Term Clinical Outcome in Familial and Sporadic Papillary Thyroid Carcinoma. European Thyroid Journal, 2020, 9, 213-220.	1.2	8
30	Skin Metastases from Anaplastic Thyroid Carcinoma. Thyroid, 2006, 16, 513-514.	2.4	5
31	Calcitonin Levels in Thyroid Disease Are Not Affected by Autoimmune Thyroiditis or Differentiated Thyroid Carcinoma. European Thyroid Journal, 2021, 10, 295-305.	1.2	5
32	Role of Age at Diagnosis in Defining Potential Familial Nonmedullary Thyroid Cancer in Kindreds With Two Affected Members. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e855-e865.	1.8	5
33	The Combination of Sonographic Features and the Seven-Gene Panel May be Useful in the Management of Thyroid Nodules With Indeterminate Cytology. Frontiers in Endocrinology, 2021, 12, 613727.	1.5	5
34	Improvement of Overall Survival Using TKIs as Salvage Therapy in Advanced Thyroid Carcinoma: Real-Life Data on a Single Center Experience. Journal of Clinical Medicine, 2021, 10, 384.	1.0	4
35	Autosomal dominant familial neurohypophyseal diabetes insipidus caused by a novel missense mutation in AVP gene in a large Italian kindred. Endocrine, 2021, 74, 188-192.	1.1	3
36	Pregnancy-associated plasma protein A mRNA expression as a marker for differentiated thyroid cancer: results from a "surgical―and a "cytological―series. Journal of Endocrinological Investigation, 2021, , 1.	1.8	3

#	Article	IF	CITATIONS
37	Risk of Second Malignant Neoplasm in Familial Non-Medullary Thyroid Cancer Patients. Frontiers in Endocrinology, 2022, 13, 845954.	1.5	3
38	Clinical features of pediatric familial non-medullary thyroid cancer (FNMTC). Journal of Endocrinological Investigation, 2021, 44, 2319-2321.	1.8	2
39	Search for genetic mutations in cytological samples from thyroid nodules as a diagnostic tool: Reality, hope or myth?. Journal of Endocrinological Investigation, 2010, 33, 576-578.	1.8	1
40	Preliminary results from whole-genome expression analysis in patients with secondary adrenal insufficiency treated with modified-release hydrocortisone. Endocrine, 2021, 73, 177-185.	1.1	1
41	Indication for radioiodine remnant ablation in differentiated thyroid cancer patients: does 2018 Italian consensus change anything?. Journal of Endocrinological Investigation, 2021, 44, 139-144.	1.8	0